Ascendis Pharma A/S
Ascendis Pharma develops therapeutics using TransCon technology, a prodrug approach that extends drug half-life.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 12Latest story
November 2026
August 2026
July 2026
Ascendis Pharma develops therapeutics using TransCon technology, a prodrug approach that extends drug half-life.
November 2026
August 2026
July 2026